NeoGenomics’ Houston (TX) center of excellence achieves ERIC requirements for certification of Immunoglobulin (IG) mutation testing in CLL samples
We have a dedicated department of quality professionals who manage and administer key elements of our QMS, such as:
Licensure & credentialing
Training & competency
Sample chain of custody
All tests are developed and validated in full compliance with all federal, state and local laws, rules and regulations, including CLIA and CAP standards. Test performance is routinely and closely monitored to ensure the timely delivery of accurate test results to our clients and their patients.
All NeoGenomics clinical laboratory personnel are required to have appropriate credentials and experience to perform the tests provided by NeoGenomics. In addition, all NeoGenomics personnel are required to participate in continual training and competency programs to ensure that each employee remains proficient and qualified to perform all testing with optimal expertise.
NeoGenomics adheres to Lean and Six Sigma processes to ensure its continued excellence in services and reduce obstacles throughout our process. In addition, we regularly survey our clients and suppliers to make sure we maintain high levels of service.
Our pathology staff have received in-depth training and are certified by equipment manufacturers to perform our FDA-approved companion diagnostic assays.
NeoGenomics is a publicly-traded company (NASDAQ:NEO) and abides by all regulations that help provide transparency to shareholders and investors. NeoGenomics has successfully completed four FDA audits at our Fort Myers and Aliso Viejo facilities with no FDA form 483’s.
2016 – Aliso Viejo
2016 - Fort Myers
2013 – Aliso Viejo
2011 – Aliso Viejo
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients